Skip to main content
. 2020 Jul 8;22(9):431–440. doi: 10.1016/j.neo.2020.06.009

Fig. 2.

Fig. 2

Pamiparib shows specific growth inhibitory effects in HR deficient and BRAC mutant cell lines. (A) The anti-proliferative activity of pamiparib in several tumor cell lines. IC50 values indicate that pamiparib potently inhibited the tumor cells with HR-deficiency or BRAC mutants. For all experiments, viability was derived after 7 days of continuous treatment with pamiparib.